Reports
Sale
North America Chlorpheniramine Maleate Market Size, Share: By Dosage Form: Tablets, Syrup, Eye Drops, Others; By Application: Allergy, Hay Fever, Common Cold, Watery Eyes, Itchy Throat /Skin, Anaphylactic Shock, Urticaria, Others; By End User; By Distribution Channel; Regional Analysis; Market Dynamics; Supplier Landscape; 2024-2032
North America Chlorpheniramine Maleate Market Outlook
The global chlorpheniramine maleate market size was valued at USD 514.9 million in 2023, with North America holding a significant market share. The market is driven by the rising prevalence of allergic conditions. It is expected to grow at a CAGR of 5.7% during the forecast period of 2024-2032, with the values likely to attain USD 848.1 million by 2032.
Key Takeaways
- In the United States, allergic rhinitis affects 20-30% of adults and around 40% of children. This rising prevalence of allergic conditions is expected to directly impact the market demand.
- The launch of innovative medicines, with chlorpheniramine maleate as an essential ingredient, is likely to augment the North America chlorpheniramine maleate market share . In September 2023, Genexa introduced the Kids’ Daytime + Nighttime Cough Relief Value Pack with the nighttime product containing 2 mg of chlorpheniramine maleate.
- Robust research efforts are anticipated to lead to a broader range of chlorpheniramine maleate-based medications entering the market. In September 2023, Dr. Ferrer Biopharma revealed the potential of Intranasal Chlorpheniramine Maleate (iCPM) in reducing post-COVID symptoms by 90%, in comparison to a placebo.
North America Chlorpheniramine Maleate Market Analysis
Chlorpheniramine maleate is an antihistamine that is commonly used to relieve symptoms such as watery eyes, runny nose, common cold, and rash from allergies, among others. It works by blocking a chemical released during an allergic reaction called histamine. Heightened patient awareness regarding allergy management, increased access to medications, and rising disposable incomes are some of the factors that are contributing to the North America chlorpheniramine maleate market growth.
The market is also driven by the rising prevalence of various allergic conditions such as seasonal allergies and allergic rhinitis in North America. Population studies reveal that allergic rhinitis is highly prevalent in the United States, with the condition affecting 20-30% of adults and around 40% of children. Moreover, allergic rhinitis treatment takes a significant portion of healthcare costs. Thus, the increasing cases of such allergic conditions are expected to impact the market demand for chlorpheniramine maleate in the coming years.
The North America chlorpheniramine maleate market demand is experiencing a surge, owing to the advancement of drug formulations that supports the development of highly effective chlorpheniramine maleate products with reduced side effects. In September 2023, Genexa, a clean medicine company based in the United States, introduced new clean over the counter (OTC) medicines for kids, which included Kids’ Daytime + Nighttime Cough Relief Value Pack. The nighttime product in the value pack contains 15 mg of dextromethorphan HBr and 2 mg of chlorpheniramine maleate. The oral product does not contain any artificial fillers compared to the competitors’ products and is effective for cough management and relieves sneezing and runny nose. The launch of such innovative medicines, having chlorpheniramine maleate as an essential ingredient, is likely to augment the market value in the forecast period.
One of the major North America chlorpheniramine maleate market trends is the increased investment in research and development of chlorpheniramine maleate-based products by the key market players. In September 2023, Dr. Ferrer Biopharma, a leading pharmaceutical company in Florida, revealed the potential of Intranasal Chlorpheniramine Maleate (iCPM) in treating post-COVID-19 long-term symptoms. The findings from two randomized controlled trials (ACCROS I and ACCROS III) were presented at the European Respiratory Society (ERS) Congress 2023. It demonstrated intranasal chlorpheniramine's ability to reduce post-COVID symptoms by 90% compared to placebo. Such intensive research efforts are anticipated to lead to a broader range of chlorpheniramine maleate-based medications entering the market, thereby boosting market growth.
North America Chlorpheniramine Maleate Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
| Market Breakup | Categories |
| Dosage Form | Tablets, Syrup, Eye Drops, Others |
| Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others |
| Application | Allergy, Hay Fever, Common Cold, Watery Eyes, Itchy Throat/Skin, Anaphylactic Shock, Urticaria, Others |
| End User | Pharmaceutical and Biotechnology Companies, Contract Research Organization, Academic and Research Institutes, Others |
| Countries | United States of America, Canada |
North America Chlorpheniramine Maleate Market: Competitor Landscape
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Pfizer Inc.
- Johnson & Johnson
- Sanofi
- Zydus Lifesciences Limited
- GlaxoSmithKline Plc
- Capellon Pharmaceuticals
- Merck & Co., Inc.
- Alkem Laboratories Ltd.
- Viatris Inc.
- Bayer AG
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Dosage Form |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 North America Chlorpheniramine Maleate Market Overview
3.1 North America Chlorpheniramine Maleate Market Historical Value (2017-2023)
3.2 North America Chlorpheniramine Maleate Market Forecast Value (2024-2032)
4 North America Chlorpheniramine Maleate Market Landscape*
4.1 North America Chlorpheniramine Maleate Market: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 North America Chlorpheniramine Maleate Market: Product Landscape
4.2.1 Analysis by Dosage Form
4.2.2 Analysis by Application
5 North America Chlorpheniramine Maleate Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Analysis
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 North America Chlorpheniramine Maleate Market Segmentation (2017-2032)
6.1 North America Chlorpheniramine Maleate Market (2017-2032) by Dosage Form
6.1.1 Market Overview
6.1.2 Tablets
6.1.3 Syrup
6.1.4 Eye Drops
6.1.5 Others
6.2 North America Chlorpheniramine Maleate Market (2017-2032) by Application
6.2.1 Market Overview
6.2.2 Allergy
6.2.3 Hay Fever
6.2.4 Common Cold
6.2.5 Watery Eyes
6.2.6 Itchy Throat /Skin
6.2.7 Anaphylactic Shock
6.2.8 Urticaria
6.2.9 Others
6.3 North America Chlorpheniramine Maleate Market (2017-2032) by End User
6.3.1 Market Overview
6.3.2 Pharmaceutical and Biotechnology Companies
6.3.3 Contract Research Organization
6.3.4 Academic and Research Institutes
6.3.5 Others
6.4 North America Chlorpheniramine Maleate Market (2017-2032) by Distribution Channel
6.4.1 Market Overview
6.4.2 Hospital Pharmacies
6.4.3 Retail Pharmacies
6.4.4 Online Pharmacies
6.4.5 Others
6.5 North America Chlorpheniramine Maleate Market (2017-2032) by Countries
6.5.1 Market Overview
6.5.2 United States of America
6.5.3 Canada
7 United States of America Biosimulation Market (2017-2032)
7.1 United States of America Chlorpheniramine Maleate Market (2017-2032) by Dosage Form
7.1.1 Market Overview
7.1.2 Tablets
7.1.3 Syrup
7.1.4 Eye Drops
7.1.5 Others
7.2 United States of America Chlorpheniramine Maleate Market (2017-2032) by Application
7.2.1 Market Overview
7.2.2 Allergy
7.2.3 Hay Fever
7.2.4 Common Cold
7.2.5 Watery Eyes
7.2.6 Itchy Throat /Skin
7.2.7 Anaphylactic Shock
7.2.8 Urticaria
7.2.9 Others
7.3 United States of America Chlorpheniramine Maleate Market (2017-2032) by End User
7.3.1 Market Overview
7.3.2 Pharmaceutical and Biotechnology Companies
7.3.3 Contract Research Organization
7.3.4 Academic and Research Institutes
7.4 United States of America Chlorpheniramine Maleate Market (2017-2032) by Distribution Channel
7.4.1 Market Overview
7.4.2 Hospital Pharmacies
7.4.3 Retail Pharmacies
7.4.4 Online Pharmacies
7.4.5 Others
8 Canada Chlorpheniramine Maleate Market (2017-2032)
8.1 Canada Chlorpheniramine Maleate Market (2017-2032) by Dosage Form
8.1.1 Market Overview
8.1.2 Tablets
8.1.3 Syrup
8.1.4 Eye Drops
8.1.5 Others
8.2 Canada Chlorpheniramine Maleate Market (2017-2032) by Application
8.2.1 Market Overview
8.2.2 Allergy
8.2.3 Hay Fever
8.2.4 Common Cold
8.2.5 Watery Eyes
8.2.6 Itchy Throat /Skin
8.2.7 Anaphylactic Shock
8.2.8 Urticaria
8.2.9 Others
8.3 Canada Chlorpheniramine Maleate Market (2017-2032) by End User
8.3.1 Market Overview
8.3.2 Pharmaceutical and Biotechnology Companies
8.3.3 Contract Research Organization
8.3.4 Academic and Research Institutes
8.4 Canada Chlorpheniramine Maleate Market (2017-2032) by Distribution Channel
8.4.1 Market Overview
8.4.2 Hospital Pharmacies
8.4.3 Retail Pharmacies
8.4.4 Online Pharmacies
8.4.5 Others
9 Regulatory Framework
10 Patent Analysis
10.1 Analysis by Type of Patent
10.2 Analysis by Publication year
10.3 Analysis by Issuing Authority
10.4 Analysis by Patent Age
10.5 Analysis by CPC Analysis
10.6 Analysis by Patent Valuation
10.7 Analysis by Key Players
11 Funding and Investment Analysis
11.1 Analysis by Funding Instances
11.2 Analysis by Type of Funding
11.3 Analysis by Funding Amount
11.4 Analysis by Leading Players
11.5 Analysis by Leading Investors
11.6 Analysis by Geography
12 Partnership and Collaborations Analysis
12.1 Analysis by Partnership Instances
12.2 Analysis by Type of Partnership
12.3 Analysis by Leading Players
12.4 Analysis by Geography
13 Supplier Landscape
13.1 Market Share by Top 5 Companies
13.2 Pfizer Inc.,
13.2.1 Financial Analysis
13.2.2 Product Portfolio
13.2.3 Demographic Reach and Achievements
13.2.4 Mergers and Acquisitions
13.2.5 Certifications
13.3 Johnson & Johnson
13.3.1 Financial Analysis
13.3.2 Product Portfolio
13.3.3 Demographic Reach and Achievements
13.3.4 Mergers and Acquisitions
13.3.5 Certifications
13.4 Sanofi
13.4.1 Financial Analysis
13.4.2 Product Portfolio
13.4.3 Demographic Reach and Achievements
13.4.4 Mergers and Acquisitions
13.4.5 Certifications
13.5 Zydus Lifesciences Limited
13.5.1 Financial Analysis
13.5.2 Product Portfolio
13.5.3 Demographic Reach and Achievements
13.5.4 Mergers and Acquisitions
13.5.5 Certifications
13.6 GlaxoSmithKline Plc
13.6.1 Financial Analysis
13.6.2 Product Portfolio
13.6.3 Demographic Reach and Achievements
13.6.4 Mergers and Acquisitions
13.6.5 Certifications
13.7 Capellon Pharmaceuticals
13.7.1 Financial Analysis
13.7.2 Product Portfolio
13.7.3 Demographic Reach and Achievements
13.7.4 Mergers and Acquisitions
13.7.5 Certifications
13.8 Merck & Co., Inc.
13.8.1 Financial Analysis
13.8.2 Product Portfolio
13.8.3 Demographic Reach and Achievements
13.8.4 Mergers and Acquisitions
13.8.5 Certifications
13.9 Alkem Laboratories Ltd.
13.9.1 Financial Analysis
13.9.2 Product Portfolio
13.9.3 Demographic Reach and Achievements
13.9.4 Mergers and Acquisitions
13.9.5 Certifications
13.10 Viatris Inc.
13.10.1 Financial Analysis
13.10.2 Product Portfolio
13.10.3 Demographic Reach and Achievements
13.10.4 Mergers and Acquisitions
13.10.5 Certifications
13.11 Bayer AG
13.11.1 Financial Analysis
13.11.2 Product Portfolio
13.11.3 Demographic Reach and Achievements
13.11.4 Mergers and Acquisitions
13.11.5 Certifications
14 North America Chlorpheniramine Maleate Market – Distribution Model (Additional Insight)
14.1 Overview
14.2 Potential Distributors
14.3 Key Parameters for Distribution Partner Assessment
15 Key Opinion Leaders (KOL) Insights (Additional Insight)
16 Company Competitiveness Analysis (Additional Insight)
16.1 Very Small Companies
16.2 Small Companies
16.3 Mid-Sized Companies
16.4 Large Companies
16.5 Very Large Companies
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The North America chlorpheniramine maleate market is expected to be driven by the rising demand for the global chlorpheniramine maleate market, which is anticipated to grow at a CAGR of 5.7% during the forecast period of 2024-2032 and is likely to reach a market value of USD 848.1 million by 2032.
Heightened patient awareness regarding allergy management and rising disposable incomes are fuelling the demand for the market.
One of the significant trends in the market is the increased investment in research and development of chlorpheniramine maleate-based products by the key market players. In September 2023, Dr. Ferrer Biopharma revealed the potential of Intranasal Chlorpheniramine Maleate (iCPM) in reducing post-COVID symptoms by over 90% compared to a placebo.
Based on the dosage form, the market is segmented into tablets, syrup, and eye drops, among others.
Distribution channels in the market include hospital pharmacies, retail pharmacies, and online pharmacies, among others.
End users of the market are pharmaceutical and biotechnology companies, contract research organizations, academic, and research institutes, among others.
Major application areas of chlorpheniramine maleate include allergy, hay fever, common cold, watery eyes, itchy throat/skin, anaphylactic shock, and urticaria, among others.
The market segmentation by countries includes the United States of America and Canada.
The key players in the market are Pfizer Inc., Johnson & Johnson, Sanofi, Zydus Lifesciences Limited, GlaxoSmithKline Plc, Capellon Pharmaceuticals, Merck & Co., Inc., Alkem Laboratories Ltd., Viatris Inc., and Bayer AG.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2639
$2399
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 4399
$3999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 5829
$5299
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 6929
$6299
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER